Status:
COMPLETED
A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer
Lead Sponsor:
Eisai Korea Inc.
Conditions:
Stomach Ulcer
Duodenal Ulcer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to understand the following safety related particulars associated with the use of Pariet Tablet 5 milligram (mg) to prevent gastric and duodenal ulcer from low dose aspiri...
Eligibility Criteria
Inclusion
- Participants aged over 18 years
- Participants who have a history of gastric and duodenal ulcer falling under the approved indication for Pariet Tablet 5 mg and who are receiving Pariet Tablet 5 mg to prevent gastric and duodenal ulcer from low dose aspirin use of 100 mg or less daily
- Participants whose prescription of Pariet Tablet 5 mg has been determined before study participation
- Participants who have given written consent to the use of their personal and medical information
Exclusion
- Participants with a known hypersensitivity to rabeprazole sodium, any excipients used in the formulation or benzimidazole derivatives, and with the history of such hypersensitivity
- Participants administered with atazanavir
- Pregnant or lactating
- Participants administered with rilpivirine
- Participants currently participating in other clinical trials
Key Trial Info
Start Date :
July 23 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 22 2022
Estimated Enrollment :
676 Patients enrolled
Trial Details
Trial ID
NCT05208268
Start Date
July 23 2020
End Date
September 22 2022
Last Update
November 22 2022
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Site #09
Bucheon-si, Gyeongji-do, South Korea
2
Site #31
Bucheon-si, Gyeongji-do, South Korea
3
Site #24
Dongtan, Gyeongji-do, South Korea
4
Site #03
Ilsan, Gyeongji-do, South Korea